Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17440291 | 1.00 | MMP2 (0.35) | MMP2ANPEPPAX8 | |
| SCHEMBL17440285 | 1.00 | MMP2 (0.35) | MMP2ANPEPPAX8 | |
| SCHEMBL17440309 | 0.73 | NR1H4 (0.32) | PAX8 | |
| SCHEMBL17440249 | 0.73 | NR1H4 (0.32) | PAX8 | |
| SCHEMBL17440235 | 0.73 | NR1H4 (0.32) | PAX8 | |
| SCHEMBL17440292 | 0.73 | — | — | |
| SCHEMBL23459320 | 0.72 | FFAR3 (0.46) | MMP2ANPEP | |
| SCHEMBL23459427 | 0.68 | MMP2 (0.39) | MMP2ANPEP | |
| SCHEMBL8969379 | 0.68 | POLA1 (0.37) | MMP2 | |
| SCHEMBL15657394 | 0.67 | MMP2 (0.38) | MMP2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908895-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2018-03-06 | — | — | US | disclosed |
| US-20160024109-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE HOLDINGS CORPORATION | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024109-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | MMP2 4345/4885ANPEP 1425/4885PAX8 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.